Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

L6292

Sigma-Aldrich

Lisinopril

≥98% (HPLC)

Sinonimo/i:

(S)-1-[N2-(1-carboxy-3-phenylpropyl)-lysyl-proline dihydrate, MK-521

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C21H31O5N3 · 2H2O
Numero CAS:
83915-83-7
Peso molecolare:
441.52
Numero MDL:
MFCD01698825
Codice UNSPSC:
12352200
ID PubChem:
329817636
NACRES:
NA.32

Saggio

≥98% (HPLC)

Forma fisica

solid

Colore

white

Solubilità

H2O: ≥10 mg/mL
DMSO: ~6.5 mg/mL (with heating and sonicating)

Temperatura di conservazione

2-8°C

Stringa SMILE

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1
CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Informazioni sul gene

human ... ACE(1636)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Lisinopril has been used to study the antifibrotic effect in duchenne muscular dystrophy mice. It has been used to study the changes in renal-structure and -function in TGR(mRen2)27 (transgenic rat harboring the murine Ren-2 gene) rats upon long term darbepoetin α treatment.

Azioni biochim/fisiol

Angiotensin converting enzyme (ACE) inhibitor.

Caratteristiche e vantaggi

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Health hazard
GHS08

Avvertenze

Danger

Indicazioni di pericolo

H360D,H373

Classi di pericolo

Repr. 1A - STOT RE 2

Organi bersaglio

Kidney

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

Trandolapril ≥98% (HPLC), white, powder

Sigma-Aldrich

T4827

Trandolapril

Benazepril hydrochloride ≥98% (HPLC), solid

Sigma-Aldrich

B0935

Benazepril hydrochloride

Enalapril maleate salt powder, ≥98% (TLC)

Sigma-Aldrich

E6888

Enalapril maleate salt

Enalaprilat dihydrate ≥98% (HPLC)

Sigma-Aldrich

E9658

Enalaprilat dihydrate

Valsartan ≥98% (HPLC)

Sigma-Aldrich

SML0142

Valsartan

Captopril Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1307

Captopril

Carvedilol ≥98% (HPLC), solid

Sigma-Aldrich

C3993

Carvedilol

Losartan Potassium

Supelco

61188

Losartan Potassium

Anne-Roos S Frenay et al.
Journal of the renin-angiotensin-aldosterone system : JRAAS, 13(2), 232-238 (2012-01-28)
Erytropoietin (EPO) has cytoprotective and angiogenic properties and has a beneficial effect in ischaemic conditions. Since the development of renal interstitial abnormalities are often associated with ischaemia, we studied the effects of the long-acting EPO analogue darbepoetin alpha (DA) on
Jason V Baker et al.
PloS one, 7(10), e46894-e46894 (2012-10-20)
Treatments that reduce inflammation and cardiovascular disease (CVD) risk among individuals with HIV infection receiving effective antiretroviral therapy (ART) are needed. We conducted a 2 × 2 factorial feasibility study of lisinopril (L) (10 mg daily) vs L-placebo in combination
Jill A Rafael-Fortney et al.
Circulation, 124(5), 582-588 (2011-07-20)
Nearly universal cardiomyopathy in Duchenne muscular dystrophy (DMD) contributes to heart failure and death. Because DMD patients show myocardial fibrosis well before functional impairment, we postulated that earlier treatment using drugs with antifibrotic effect may be beneficial. Three groups of
Tatjana Ignjatovic et al.
The Journal of biological chemistry, 277(19), 16847-16852 (2002-03-07)
Angiotensin I converting enzyme (kininase II; ACE) inhibitors are important therapeutic agents widely used for treatment in cardiovascular and renal diseases. They inhibit angiotensin II release and bradykinin inactivation; these actions do not explain completely the clinical benefits. We found
Nadir Ulu et al.
The Journal of pharmacology and experimental therapeutics, 345(3), 393-403 (2013-03-27)
Transactivation of epidermal growth factor receptor (EGFR) signaling by G protein-coupled receptors has been implicated in several cardiovascular (CV) conditions, including hypertension, heart failure, and cardiac and vascular hypertrophy. However, the therapeutic potential of EGFR inhibition in these conditions is
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.